We are Sorry, This Page doesn't Exist

Ionis Pharmaceuticals, AstraZeneca advance new drug for NASH

See the rest of the story here. provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallApr 9th, 2018

Ionic Pharmaceuticals shares jump 3% premarket on news of license deal with AstraZeneca

Ionis Pharmaceuticals Inc. shares rose 3% premarket Monday, after the company unveiled a licensing deal with AstraZeneca PlC for a treatment for nonalcoholic steatohepatitis (NASH), or fatty liver. Ionis said it will receive .....»»

Category: topSource: marketwatchApr 9th, 2018

Ionis Pharmaceuticals licences new antisense drug to AstraZeneca

See the rest of the story here. provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallFeb 20th, 2018

Indian firm a front-runner to acquire Mallinckrodt"s generic drug business: Report

India-based Intas Pharmaceuticals reportedly has emerged as a front-runner to acquire Mallinckrodt's generic drug business in a deal that could be worth $1.5 billion. Intas, the largest privately held pharmaceutical company in India, is one of two bi.....»»

Category: topSource: bizjournalsNov 2nd, 2017

Novartis to Pay $3.9 Billion for Radio-Pharmaceuticals Firm

Novartis said it has agreed to acquire Advanced Accelerator Applications for $3.9 billion, a deal that would boost its oncology portfolio as generic competition eats into sales of blockbuster blood-cancer drug Gleevec......»»

Category: smallbizSource: wsjOct 30th, 2017

Wall Street"s most hated pharma company just lost a lifeline

Markets InsiderA court ruling on Tuesday left Mallinckrodt Pharmaceuticals without protection from 11 patents on its drug Inomax, a hypoxic respiratory failure drug that made up 15% of the company's r.....»»

Category: topSource: businessinsiderSep 5th, 2017

AstraZeneca and Takeda Ink Deal to Develop Parkinson"s Drug

AstraZeneca (AZN) and Takeda Pharmaceutical Company entered into an agreement to jointly develop and .....»»

Category: personnelSource: nytAug 30th, 2017

Mystery at AstraZeneca: Is CEO Pascal Soriot Staying or Going?

Shares in the U.K. drug giant fell sharply after a news outlet reported he was moving to lead Teva Pharmaceuticals, an Israeli generics drugmaker that has been looking for a new chief for months......»»

Category: smallbizSource: wsjJul 13th, 2017

AstraZeneca slips 1% after disappointing cancer-drug trial

This is a Real-time headline. These are breaking news, delivered the minute it happens, delivered ticker-tape style. Visit or the quote page for more information about this breaking news......»»

Category: topSource: marketwatchApr 24th, 2018

Synergy Pharmaceuticals: Best Drug + Terrible Management = Terrible Investment

Synergy Pharmaceuticals: Best Drug + Terrible Management = Terrible Investment.....»»

Category: topSource: seekingalphaApr 23rd, 2018

Fight against opioids impacts workers" comp spending, myMatrixx report finds

Workers’ compensation spending on pharmaceuticals dropped 3.3 percent in 2017 compared to 2016, according to a new drug trend report from myMatrixx, a pharmacy benefits provider that is part of Express Scripts Holding Co.. Drug use by injured work.....»»

Category: topSource: bizjournalsApr 23rd, 2018

HC Wainwright Says Aerpio Pharma Flies Under The Radar Due To OTC Listing, Projects 150% Upside

Aerpio Pharmaceuticals Inc (OTC: ARPO), an OTC-listed company specializing in drug development for ocular diseases, earned a bullish review Wednesday. The interest in the stock can only go higher, as the company seeks to up-list the shares.....»»

Category: blogSource: benzingaApr 21st, 2018

Biogen boosts investment in neurology with $1 billion Ionis deal

(Reuters) - U.S. drugmaker Biogen Inc rolled out part of its $37 billion investment warchest on Friday, signing a $1 billion deal that seeks to expand on the strength of an existing partnership with Ionis Pharmaceuticals Inc......»»

Category: topSource: reutersApr 20th, 2018

Ionis Pharmaceuticals" stock soars as Biogen collaboration deal includes $1 billion payment

Shares of Ionis Pharmaceuticals Inc. soared 8.4% in p.....»»

Category: topSource: marketwatchApr 20th, 2018

Biogen, Ionis Pharmaceuticals expand drug development collaboration

See the rest of the story here. provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallApr 20th, 2018

"An Incredible Signal": 4 Experts Weigh In On Positive FDA Panel Vote For GW Pharma"s Epidiolex

Shares of GW Pharmaceuticals PLC- ADR (NASDAQ: GWPH) were halted Thursday, ahead of a Food and Drug Administration vote on the company's cannabis-derived drug Epidiolex. read more.....»»

Category: blogSource: benzingaApr 19th, 2018

GW Pharma wins unanimous recommendation from FDA advisory committee for cannabis-derived drug

GW Pharmaceuticals PLC said Thursday it has won a unanimous recommendation from a U.S. Food and Drug Administration advisory committee for the approval of its cannabis-derived drug epidi.....»»

Category: topSource: marketwatchApr 19th, 2018

Why GW Pharmaceuticals Isn’t Moving, Despite a Big First for the FDA

GW Pharmaceuticals won an FDA approval for its cannabis-derived drug, but shares were relatively muted on Thursday......»»

Category: blogSource: 247wallstApr 19th, 2018

The next mega merger could be a $60 billion drug deal

Shares in drug company Shire surged in London as Japan's Takeda and Allergan consider bidding......»»

Category: topSource: cnnApr 19th, 2018

As part of $4.2-bn global deal, P&G to acquire Merck India for Rs 12.9 bn

Deal part of its $4.2 billion global acquisition of German drug maker's consumer health business.....»»

Category: topSource: business-standardApr 19th, 2018